Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's mu...
Q1 2026
May 15, 2026
FY 2025
Mar 18, 2026
Q4 2025
Q3 2025
Nov 13, 2025
Q2 2025
Aug 14, 2025